Prof. Yu Tang 唐域
Chief Physician, Professor
Internal Medicine, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Lung cancer treatment, including chemotherapy, targeted therapy, and immunotherapy. Focuses on biomarker-guided personalized precision therapy for non-small cell lung cancer and comprehensive management of small cell lung cancer.
Dr. Tang is Director of the Third Thoracic Medicine Department at Liaoning Cancer Hospital & Institute. Holding a medical doctorate and serving as a Level III Professor and doctoral supervisor, Dr. Tang graduated from China Medical University in 1998. With nearly 30 years of experience in lung cancer care, Dr. Tang advocates multidisciplinary treatment and has published over 30 papers.
Professional roles
- Chair, Targeted Therapy Professional Committee, Liaoning Anti-Cancer Association
- Council Member, Youth Council, China Anti-Cancer Association
- Member, Targeted Therapy Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Respiratory Disease Branch, Liaoning Medical Association
Name order: in Chinese the family name comes first (Tang Yu). Papers usually list the name as Yu Tang or Tang Y.
Selected publications
23 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Transl Med, 2026 (senior author): Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer. PubMed 41888928
- Cancer Cell Int, 2024 (senior author): TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination. PubMed 38867223
- Environ Toxicol, 2024 (senior author): MicroRNA-140-3p inhibits proliferation and promotes apoptosis in non-small cell lung cancer by targeting MDIG. PubMed 38009637
- J Transl Med, 2023 (first author): GSG2 facilitates the progression of human breast cancer through MDM2-mediated ubiquitination of E2F1. PubMed 37537694
- Cancer, 2020 (first author): Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes. PubMed 32710662
- J Immunother, 2020 (senior author): Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients. PubMed 32168233
- Tumour Biol, 2014 (first author): Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy. PubMed 24899263
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion